YANTAI, CHINA - Media OutReach - 28 March 2023 - Boan Biotech (6955.HK) announced its 2022 financial results and recent business developments on March 27, 2023. 2022 business.
Showing accelerated innovation and strong 225% revenue growth YANTAI, China, March 27, 2023 /PRNewswire/ Boan Biotech (6955.HK) today announced its 2022 financial results and recent business developments. 2022 business highlights Eye-catching performance of two marketed products Boan Biotech's first drug Boyounuo (bevacizumab injection, a biosimilar to Avastin®) is used for the treatment of multiple cancers. Sales grew rapidly.